Previous close | 95.50 |
Open | 95.50 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 90.00 |
Expiry date | 2023-07-21 |
Day's range | 95.50 - 95.50 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.